Q-omics provides the consensus-scored KLK3 profile across patient tissues and cancer cell-line models. KLK3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KLK3 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, KLK3 RNA expression shows 6,761 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KICH, and DLBC as cancer lineages where KLK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK3 survival associations across molecular data types. KLK3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK3 RNA expression–survival associations across cancer types. High KLK3 expression shows unfavorable associations in OV, KIRC, CESC, CHOL and DLBC, but favorable associations in ACC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KLK3 RNA expression.
This table summarizes KLK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KLK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK3 shows lower tumor expression in COAD, BRCA, THCA, KIRP and KIRC and higher tumor expression in KICH. The KICH box plot shows higher KLK3 RNA expression in tumor versus normal tissue (log2 FC = +3.117, t-test p < 0.001).
This table shows molecular features associated with KLK3 in patient tissues and cancer cell lines. In patient samples, KLK3 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
